Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
C4 Therapeutics, Inc. reported equity compensation activity for Chief Medical Officer Leonard Reyno. On July 10, 2026, Reyno acquired 15,325 shares of common stock upon vesting of previously granted restricted stock units. In a related move, 7,397 shares were withheld by the company to cover tax obligations associated with this vesting, which the company states does not represent an open-market sale.
Anderson Kenneth Carl reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics, Inc. director Kenneth C. Anderson received an equity award of common stock rather than cash fees for his board service. On July 1, 2026, he was granted 2,650 shares at a value based on the closing market price of $4.34 per share, in line with the company’s Non-Employee Director Compensation Policy. Following this compensation grant, Anderson directly holds 71,950 common shares. Additional shares are held indirectly through several Anderson family revocable and irrevocable trusts, for which he disclaims beneficial ownership except for any pecuniary interest.
GROGAN DONNA ROY reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics director Donna Roy Grogan received a grant of 3,341 shares of common stock on July 1, 2026. The shares were issued under the company’s Non-Employee Director Compensation Policy, as she elected stock instead of cash fees, bringing her direct holdings to 74,853 shares.
C4 Therapeutics, Inc. director Owen Hughes received a grant of stock options covering 62,000 shares of common stock. The options have an exercise price of $4.2500 per share and expire on June 23, 2036. Following this grant, Hughes holds options on 62,000 shares directly.
According to the vesting terms, the option becomes fully exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, provided Hughes continues serving on the Board through that date.
C4 Therapeutics, Inc. director Steven L. Hoerter received a grant of stock options covering 62,000 shares of Common Stock. The options have an exercise price of $4.25 per share and expire on June 23, 2036.
According to the footnote, the entire option vests and becomes exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, assuming he continues to serve on the Board through that date. After this grant, he holds 62,000 options directly.
C4 Therapeutics, Inc. director Utpal Koppikar received a grant of stock options to buy 62,000 shares of common stock. The options have an exercise price of $4.25 per share and expire on June 23, 2036.
The option award will vest and become exercisable in full on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, as long as he continues serving on the Board through that date. Following this grant, he holds options covering 62,000 shares directly.
C4 Therapeutics director Kenneth Carl Anderson received a grant of stock options as part of his compensation. The award covers 62,000 options to buy Common Stock at an exercise price of $4.25 per share, with no cash paid at grant.
The options vest and become exercisable in full on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, provided he continues serving on the Board through that date. The options expire on June 23, 2036 if not exercised.
C4 Therapeutics director Ronald Harold Wilfred Cooper received a grant of stock options covering 62,000 shares of common stock. The options have an exercise price of $4.25 per share and were awarded at no cost to him.
These options vest and become fully exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, as long as he continues serving on the board through that date. After this grant, his reported holdings of this option award total 62,000 derivative securities.
C4 Therapeutics director Laura Bessen received a new stock option grant covering 62,000 shares of common stock. The option has an exercise price of $4.25 per share and expires on June 23, 2036. This is a compensation-related award, not an open‑market trade.
According to the terms, the option vests and becomes fully exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, as long as Bessen continues serving on the board through that date. After this grant, she holds 62,000 derivative securities directly.
C4 Therapeutics director Stephen Fawell was granted stock options linked to 62,000 shares of common stock. The options carry an exercise price of $4.25 per share and expire on June 23, 2036. This is a compensation-related award, not an open-market purchase.
The option grant vests and becomes exercisable in full on the earlier of June 24, 2027 or the next annual meeting of stockholders, as long as he continues serving on the Board. Following this grant, he holds options covering 62,000 shares directly.